Psychotic disorders are characterized by disturbances in perception, belief formation, thought organization, and sense of reality. Core features may include delusions, hallucinations, disorganized thinking, disorganized behavior, and impairments in emotional expression, motivation, and social functioning.
Contemporary models distinguish several symptom domains, including positive symptoms, negative symptoms, cognitive impairment, affective symptoms, and general psychopathology. In contrast to subclinical psychotic-like experiences, psychotic disorders involve greater severity, persistence, functional impairment, and need for clinical assessment.
Assessment in this domain is primarily conducted using clinician-administered instruments. Self-report and associated measures can complement professional assessment by capturing subjective experience, motivation, insight, attachment, or functioning, but they do not replace clinical evaluation.
These instruments assess core symptom domains of psychotic disorders, including positive symptoms, negative symptoms, disorganization, affective symptoms, and general psychopathology. They are primarily used in clinical assessment, research, and treatment monitoring.
The Positive and Negative Syndrome Scale (PANSS) is one of the most widely used instruments for assessing positive symptoms, negative symptoms, and general psychopathology in schizophrenia-spectrum disorders.
The Brief Psychiatric Rating Scale (BPRS) provides a shorter assessment of psychiatric symptoms, including psychotic symptoms, mood disturbance, anxiety, hostility, and behavioral changes.
The Scale for the Assessment of Positive Symptoms (SAPS) provides detailed clinician-rated assessment of positive psychotic symptoms, including hallucinations, delusions, bizarre behavior, and positive formal thought disorder.
These measures assess reduced emotional expression, avolition, anhedonia, asociality, reduced speech, and motivational deficits. They help distinguish negative symptoms from depression, medication effects, social withdrawal, or general functional decline.
The Brief Negative Symptom Scale (BNSS) provides a modern assessment of negative symptoms, including anhedonia, avolition, asociality, blunted affect, alogia, and lack of normal distress.
The Clinical Assessment Interview for Negative Symptoms (CAINS) assesses experiential and expressive negative symptoms, including motivation, pleasure, social interest, emotional expression, and speech.
The Scale for the Assessment of Negative Symptoms (SANS) provides detailed clinician-rated assessment of negative psychotic symptoms, including affective flattening, alogia, avolition-apathy, anhedonia-asociality, and attentional impairment.
The Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR) evaluates engagement, interest, and perceived competence in individuals with psychotic disorders.
These instruments assess cognitive impairment associated with schizophrenia-spectrum disorders, including attention, working memory, processing speed, verbal learning, reasoning, and real-world cognitive functioning. They require professional administration or interpretation.
The MATRICS Consensus Cognitive Battery (MCCB) is a standardized performance-based battery developed to assess cognitive domains relevant to schizophrenia research.
The Schizophrenia Cognition Rating Scale (SCoRS) is an interview-based measure assessing cognitive difficulties and their impact on daily functioning.
These instruments assess early or at-risk states that may precede or indicate increased risk for psychotic disorders. They are embedded in specialized clinical frameworks and should be distinguished from population-based measures of psychotic-like experiences in the Schizotypy and Psychotic-Like Experiences domain.
The Scale of Prodromal Symptoms (SOPS), used within the Structured Interview for Psychosis-Risk Syndromes (SIPS), evaluates attenuated psychotic symptoms and risk states.
The Comprehensive Assessment of At-Risk Mental States (CAARMS) is another structured clinical tool used in early psychosis and ultra-high-risk assessment.
These measures assess awareness of symptoms, understanding of illness, cognitive insight, subjective concepts of morbidity, and adherence to medication. They are clinically important because reduced insight may affect treatment engagement, risk assessment, and functional outcomes.
The Scale to Assess Unawareness of Mental Disorder (SUMD) assesses awareness of illness, symptoms, treatment effects, and social consequences in psychotic disorders.
The Beck Cognitive Insight Scale (BCIS) assesses self-reflectiveness and overconfidence in interpretations, capturing metacognitive aspects of belief evaluation.
These measures assess the broader clinical and social impact of psychotic disorders, including real-world functioning, occupational and social adaptation, caregiver burden, depressive symptoms, and attachment-related interpersonal processes.
The Personal and Social Performance Scale (PSP) evaluates functioning across domains such as social relationships, self-care, socially useful activities, and disturbing or aggressive behavior.
The Global Assessment of Functioning (GAF) provides a broad rating of psychological, social, and occupational functioning, historically used in DSM-IV assessment.
The Social and Occupational Functioning Assessment Scale (SOFAS) assesses social and occupational functioning separately from overall psychiatric symptom severity.
The Calgary Depression Scale for Schizophrenia (CDSS) assesses depressive symptoms in individuals with schizophrenia-spectrum disorders, helping distinguish depression from negative symptoms and medication-related effects.
The Psychosis Attachment Measure (PAM-R) assesses attachment patterns in individuals with psychotic symptoms, linking relational insecurity with distress, help-seeking, and symptom maintenance.
The Overt Aggression Scale Checklist (OASCL) assesses observable aggressive behavior in clinical and institutional settings.
The Historical, Clinical, Risk Management (HCR-20) is a structured professional judgment tool for assessing violence risk in forensic and psychiatric settings.
The Ambiguous Intentions Hostility Questionnaire (AIHQ) assesses hostile attribution bias and the tendency to interpret ambiguous social situations as intentionally harmful or threatening.
⇒ Schizotypy. Psychotic disorders overlap with schizotypy through unusual beliefs, perceptual anomalies, paranoia, and disorganization, but involve greater persistence, impairment, and clinical severity.
⇒ Dissociation may resemble psychosis through altered reality experience, detachment, or disrupted self-experience, but differs in mechanism, subjective quality, and relationship to belief conviction.
⇒ Trauma may overlap with psychosis through suspiciousness, intrusive experiences, dissociation, threat perception, and altered beliefs about safety or others' intentions.
Psychotic disorders involve multiple clinical domains: positive symptoms, negative symptoms, disorganization, cognitive impairment, affective symptoms, insight, treatment engagement, and real-world functioning.
Assessment in this area should usually be clinician-administered or professionally interpreted. Self-report and adjacent measures may add information about subjective experience, depression, attachment, motivation, or functioning, but cannot determine the presence of a psychotic disorder on their own.
Interpretation should consider symptom duration, conviction, insight, functional impairment, developmental course, mood state, substance use, medical or neurological factors, cultural context, risk, and the distinction between clinical psychosis and subclinical psychotic-like experiences.